It is our standard practice at the Mayo Clinic, Rochester, MN that any lymphoma patient undergoing ASCT will not only have enough CD34 stem cells (4.0 × 106 cells/kg) collected to facilitate hematologic engraftment but also A-ALC ≥ 0.5 × 109 cells/kg to impact ALC-15 and survival post-ASCT [55]. The gene discussed is CD34; the disease is lymphoma.